Repository logo
 
Publication

The Use of Continuous Glucose Monitoring in People Living with Obesity, Intermediate Hyperglycemia or Type 2 Diabetes.

2025-05Text Open access
Simple item page
dc.contributor.authorBattelino, Tadej
dc.contributor.authorLalic, Nebojsa
dc.contributor.authorHussain, Sufyan
dc.contributor.authorCeriello, Antonio
dc.contributor.authorKlobucar, Sanja
dc.contributor.authorDavies, Sarah J
dc.contributor.authorTopsever, Pinar
dc.contributor.authorHeverly, Julie
dc.contributor.authorUlivi, Francesca
dc.contributor.authorBrady, Kevin
dc.contributor.authorTankova, Tsvetalana
dc.contributor.authorGalhardo, Júlia
dc.contributor.authorTagkalos, Kostas
dc.contributor.authorWerson, Erik
dc.contributor.authorMathieu, Chantal
dc.contributor.authorSchwarz, Peter
dc.date.accessioned2025-08-26T15:13:23Z
dc.date.available2025-08-26T15:13:23Z
dc.date.issued2025-05
dc.description.abstractA global trend towards increased obesity, intermediate hyperglycemia (previously termed prediabetes) and type 2 diabetes, has prompted a range of international initiatives to proactively raise awareness and provide action-driven recommendations to prevent and manage these linked disease states. One approach, that has shown success in managing people already diagnosed with type 2 diabetes mellitus, is to use continuous glucose monitoring (CGM) devices to help them manage their chronic condition through understanding and treating their daily glucose fluctuations, in assocation with glucose-lowering medications, including insulin. However, much of the burden of type 2 diabetes mellitus is founded in the delayed detection both of type 2 diabetes mellitus itself, and the intermediate hyperglycemia that precedes it. In this review, we provide evidence that using CGM technology in people at-risk of intermediate hyperglycemia or type 2 diabetes mellitus can significantly improve the rate and timing of detection of dysglycemia. Earlier detection allows intervention, including through continued use of CGM to guide changes to diet and lifestyle, that can delay or prevent harmful progression of early dysglycemia. Although further research is needed to fully understand the cost-effectiveness of this intervention in people at-risk or with early dysglycemia, the proposition for use of CGM technology is clear.eng
dc.identifier.citationDiabetes Res Clin Pract . 2025; 223:112111
dc.identifier.doi10.1016/j.diabres.2025.112111
dc.identifier.other40118193
dc.identifier.urihttp://hdl.handle.net/10400.17/5150
dc.language.isoen
dc.peerreviewedyes
dc.publisherElsevier
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectConsensus statements
dc.subjectContinuous glucose monitoring
dc.subjectIntermediate hyperglycemia
dc.subjectObesity
dc.subjectPrediabetes
dc.subjectType 2 diabetes
dc.subjectHDE END PED
dc.titleThe Use of Continuous Glucose Monitoring in People Living with Obesity, Intermediate Hyperglycemia or Type 2 Diabetes.eng
dc.typetext
dspace.entity.typePublication
oaire.citation.startPage112111
oaire.citation.volume223
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Diabetes Res Clin Pract 2025_112111.pdf
Size:
849.8 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.03 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

END PED - Artigos